149 related articles for article (PubMed ID: 29207057)
21. HSP90 modulates actin dynamics: inhibition of HSP90 leads to decreased cell motility and impairs invasion.
Taiyab A; Rao ChM
Biochim Biophys Acta; 2011 Jan; 1813(1):213-21. PubMed ID: 20883729
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90.
Koga F; Kihara K; Neckers L
Anticancer Res; 2009 Mar; 29(3):797-807. PubMed ID: 19414312
[TBL] [Abstract][Full Text] [Related]
23. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.
Moser C; Lang SA; Stoeltzing O
Anticancer Res; 2009 Jun; 29(6):2031-42. PubMed ID: 19528462
[TBL] [Abstract][Full Text] [Related]
24. Hsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines.
Senju M; Sueoka N; Sato A; Iwanaga K; Sakao Y; Tomimitsu S; Tominaga M; Irie K; Hayashi S; Sueoka E
J Cancer Res Clin Oncol; 2006 Mar; 132(3):150-8. PubMed ID: 16283383
[TBL] [Abstract][Full Text] [Related]
25. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
26. Chalcone-templated Hsp90 inhibitors and their effects on gefitinib resistance in non-small cell lung cancer (NSCLC).
Jeong JH; Oh YJ; Kwon TK; Seo YH
Arch Pharm Res; 2017 Jan; 40(1):96-105. PubMed ID: 27770383
[TBL] [Abstract][Full Text] [Related]
27. Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis.
Koizumi H; Yamada T; Takeuchi S; Nakagawa T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Yano S
J Thorac Oncol; 2012 Jul; 7(7):1078-85. PubMed ID: 22592212
[TBL] [Abstract][Full Text] [Related]
28. Enhanced in vivo antitumor efficacy of dual-functional peptide-modified docetaxel nanoparticles through tumor targeting and Hsp90 inhibition.
Jiang Y; Yang N; Zhang H; Sun B; Hou C; Ji C; Zheng J; Liu Y; Zuo P
J Control Release; 2016 Jan; 221():26-36. PubMed ID: 26643616
[TBL] [Abstract][Full Text] [Related]
29. Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors.
Breinig M; Mayer P; Harjung A; Goeppert B; Malz M; Penzel R; Neumann O; Hartmann A; Dienemann H; Giaccone G; Schirmacher P; Kern MA; Chiosis G; Rieker RJ
Clin Cancer Res; 2011 Apr; 17(8):2237-49. PubMed ID: 21372220
[TBL] [Abstract][Full Text] [Related]
30. Down-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human non-small-cell lung cancer cells.
Tung CL; Chiu HC; Jian YJ; Jian YT; Chen CY; Syu JJ; Wo TY; Huang YJ; Tseng SC; Lin YW
Exp Cell Res; 2014 Apr; 322(2):345-54. PubMed ID: 24530475
[TBL] [Abstract][Full Text] [Related]
31. Heat-shock protein 90 (Hsp90) as anticancer target for drug discovery: an ample computational perspective.
Kumalo HM; Bhakat S; Soliman ME
Chem Biol Drug Des; 2015 Nov; 86(5):1131-60. PubMed ID: 25958815
[TBL] [Abstract][Full Text] [Related]
32. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.
Garg G; Khandelwal A; Blagg BS
Adv Cancer Res; 2016; 129():51-88. PubMed ID: 26916001
[TBL] [Abstract][Full Text] [Related]
33. Novel 1,6-naphthyridin-2(1H)-ones as potential anticancer agents targeting Hsp90.
Montoir D; Barillé-Nion S; Tonnerre A; Juin P; Duflos M; Bazin MA
Eur J Med Chem; 2016 Aug; 119():17-33. PubMed ID: 27153346
[TBL] [Abstract][Full Text] [Related]
34. Emerging Roles of Extracellular Hsp90 in Cancer.
Wong DS; Jay DG
Adv Cancer Res; 2016; 129():141-63. PubMed ID: 26916004
[TBL] [Abstract][Full Text] [Related]
35. mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis.
Acquaviva J; He S; Sang J; Smith DL; Sequeira M; Zhang C; Bates RC; Proia DA
Mol Cancer Res; 2014 May; 12(5):703-13. PubMed ID: 24554781
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of heat shock protein 90 exerts an antitumour effect in angiosarcoma: involvement of the vascular endothelial growth factor signalling pathway.
Yamada-Kanazawa S; Kajihara I; Fukushima S; Jinnin M; Masuzawa M; Masuzawa M; Amoh Y; Hoshina D; Abe R; Ihn H
Br J Dermatol; 2017 Aug; 177(2):456-469. PubMed ID: 28078663
[TBL] [Abstract][Full Text] [Related]
37. Intracellular signals of lung cancer cells as possible therapeutic targets.
Tanaka K; Kumano K; Ueno H
Cancer Sci; 2015 May; 106(5):489-96. PubMed ID: 25707772
[TBL] [Abstract][Full Text] [Related]
38. Impact of Posttranslational Modifications on the Anticancer Activity of Hsp90 Inhibitors.
Woodford MR; Dunn D; Miller JB; Jamal S; Neckers L; Mollapour M
Adv Cancer Res; 2016; 129():31-50. PubMed ID: 26916000
[TBL] [Abstract][Full Text] [Related]
39. Additive viability-loss following hsp70/hsc70 double interference and Hsp90 inhibition in two breast cancer cell lines.
Håvik B; Bramham CR
Oncol Rep; 2007 Jun; 17(6):1501-10. PubMed ID: 17487411
[TBL] [Abstract][Full Text] [Related]
40. Proteomic analysis of apoptosis induction in human lung cancer cells by recombinant MVL.
Li Y; Zhang B; Wang X; Yan H; Chen G; Zhang X
Amino Acids; 2011 Oct; 41(4):923-32. PubMed ID: 21069400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
